undamentalytics Newsletter
Sign in

CDT Equity Inc. (CDT) stock

Add to watchlist

Add holding +

NASDAQ: CDT Nasdaq Pharmaceuticals

CDT Equity Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 6 sales by directors and officers, last 12 monthsInsider trades

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in CDT Equity Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 183% and a beta of 1.7 against the S&P 500.
  • Heavily shorted. 11.6% of the shares available to trade are sold short (0.1 days of average volume to cover).

Price chart

  • 1 day+2.9%
  • 1 week-25.5%
  • 1 month-92.9%
  • This year-100.0%
  • 1 year-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Agreement
  3. Announcement
  4. Agreement
  5. Agreement
  6. Announcement
  7. Leadership
  8. Agreement
  9. Agreement
  10. Share issue
  11. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

CDT Equity Inc. valuation models and calculator

No model value for CDT Equity Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value CDT Equity Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11%: the 10-year Treasury yield (4.9%) plus a beta of 1.34 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare CDT Equity Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for CDT Equity Inc.: too few analysts cover it.

Positioning

Short interest
11.6%
of tradable shares
Days to cover
0.08
at average volume
Short interest, 1 month
+1250%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
38.2%
of shares
Employees
4
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
CDT−56%−99%−100%−100%
Industry peers (median)−13%−2%+9%−12%
S&P 500+26%+25%+18%+11%
Months that ended higher
CDT58%25%0%9%
S&P 50067%75%75%46%
Largest fall from a high during the year
CDT−94%−99%−100%−100%
S&P 500−10%−8%−19%−9%

Worst fall since March 28, 2022: 100% from September 21, 2023 to October 30, 2026. Getting back needed a 1873895910113% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.07 – $16625.00
From 52-week high
−100.0%
vs 50-day average
−99.3%
vs 200-day average
−100.0%
Volatility (1 year)
183%
Beta vs S&P 500
1.70

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.9M 6 trades by 2 insiders · 0% under pre-set plans
Net ▼ $2.9M net selling
Insider Date Trade Shares Price Value
Regan Andrew Chief Executive Officer August 28, 2026 Sell 29 — $0
Regan Andrew Chief Executive Officer August 28, 2026 Sell 290 — $0
Prospect Capital Securities Ltd 10% owner June 18, 2026 Sell 5,000 $0.71 $3,550
Prospect Capital Securities Ltd 10% owner June 18, 2026 Sell 593,289 $1.40 $830,605
Prospect Capital Securities Ltd 10% owner June 18, 2026 Sell 1,464,711 $1.44 $2.1M
Prospect Capital Securities Ltd 10% owner June 18, 2026 Sell 5,000 $0.75 $3,750

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on CDT Equity Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

CDT Equity Inc. in brief

What does CDT Equity Inc. do?
CDT Equity Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is CDT Equity Inc.'s stock ticker?
CDT Equity Inc. trades under the ticker CDT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Are insiders buying or selling CDT Equity Inc. stock?
Over the last 12 months, CDT Equity Inc.'s directors and officers reported 0 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.